Equities Analysts Set Expectations for MDxHealth Q1 Earnings

MDxHealth SA (NASDAQ:MDXH) – Investment analysts at William Blair issued their Q1 2026 earnings estimates for MDxHealth in a research report issued to clients and investors on Wednesday, February 26th. William Blair analyst A. Brackmann expects that the company will earn ($0.13) per share for the quarter. The consensus estimate for MDxHealth’s current full-year earnings is ($1.15) per share. William Blair also issued estimates for MDxHealth’s Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.07) EPS and Q4 2026 earnings at ($0.05) EPS.

MDxHealth (NASDAQ:MDXH) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.07. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. The business had revenue of $24.74 million during the quarter, compared to the consensus estimate of $22.67 million.

Separately, Piper Sandler lowered their price objective on MDxHealth from $8.00 to $6.00 and set an “overweight” rating for the company in a research note on Thursday, November 7th.

MDxHealth Stock Down 2.2 %

Shares of MDxHealth stock opened at $1.82 on Friday. The stock has a market capitalization of $86.06 million, a price-to-earnings ratio of -1.20 and a beta of 1.34. MDxHealth has a twelve month low of $1.55 and a twelve month high of $3.85. The company has a current ratio of 1.54, a quick ratio of 1.45 and a debt-to-equity ratio of 3.14. The business’s 50 day simple moving average is $2.01 and its 200-day simple moving average is $2.20.

Institutional Investors Weigh In On MDxHealth

Several large investors have recently made changes to their positions in MDXH. OneDigital Investment Advisors LLC grew its holdings in MDxHealth by 15.3% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,726 shares of the company’s stock worth $120,000 after buying an additional 7,656 shares in the last quarter. FAS Wealth Partners Inc. boosted its position in MDxHealth by 49.6% during the 4th quarter. FAS Wealth Partners Inc. now owns 24,425 shares of the company’s stock worth $58,000 after acquiring an additional 8,100 shares during the period. Oppenheimer & Co. Inc. grew its stake in shares of MDxHealth by 100.0% in the fourth quarter. Oppenheimer & Co. Inc. now owns 20,000 shares of the company’s stock worth $47,000 after purchasing an additional 10,000 shares in the last quarter. Geode Capital Management LLC acquired a new position in shares of MDxHealth during the fourth quarter valued at $25,000. Finally, XTX Topco Ltd bought a new stake in shares of MDxHealth during the fourth quarter valued at about $63,000.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.